Bazedoxifene acetate
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| The evolution of selective estrogen receptor modulators in osteoporosis therapy. | Climacteric : the journal of the International Menopause Society 20121201 |
| Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. | Calcified tissue international 20121001 |
| The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. | Journal of women's health (2002) 20120901 |
| Future long-term trials of postmenopausal hormone replacement therapy - what is possible and what is the optimal protocol and regimen? | Climacteric : the journal of the International Menopause Society 20120601 |
| [New approved drugs for osteoporosis in Japan]. | Clinical calcium 20120601 |
| In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes. | Chemico-biological interactions 20120415 |
| Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. | Menopause (New York, N.Y.) 20120401 |
| Bazedoxifene: a guide to its use in postmenopausal osteoporosis. | Drugs & aging 20120401 |
| An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. | Maturitas 20120301 |
| Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101 |
| The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. | Gynecologic oncology 20120101 |
| Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. | Drugs 20111112 |
| The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. | Molecular pharmacology 20111001 |
| Bone: in search of the perfect SERM--a 5-year study of bazedoxifene. | Nature reviews. Endocrinology 20110920 |
| Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. | Drugs 20110910 |
| Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. | Bone 20110901 |
| Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. | Endocrinology 20110801 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| [Diagnostic imaging of treatment in osteoporosis: SERM]. | Clinical calcium 20110701 |
| Selective estrogen receptor modulators: the future in menopausal treatment. | Minerva ginecologica 20110601 |
| [Selective estrogen receptor modulators: focus on bazedoxifene]. | Minerva ginecologica 20110601 |
| Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. | Menopause international 20110601 |
| Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. | Menopause (New York, N.Y.) 20110501 |
| Treating menopausal symptoms with a tissue-selective estrogen complex. | Gender medicine 20110401 |
| Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301 |
| Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110301 |
| Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201 |
| Efficacy and safety of bazedoxifene in postmenopausal Asian women. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201 |
| Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201 |
| The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. | Menopause (New York, N.Y.) 20110101 |
| [Bazedoxifene as a new-generation SERM]. | Clinical calcium 20110101 |
| Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. | Clinical interventions in aging 20110101 |
| Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat. | Asian Pacific journal of cancer prevention : APJCP 20110101 |
| Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women. | Expert opinion on investigational drugs 20101201 |
| Third-generation SERMs may face uphill battle. | Journal of the National Cancer Institute 20101117 |
| In vitro metabolism, permeability, and efflux of bazedoxifene in humans. | Drug metabolism and disposition: the biological fate of chemicals 20100901 |
| New selective estrogen receptor modulators (SERMs) in development. | Current osteoporosis reports 20100901 |
| Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. | Menopause international 20100901 |
| FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. | Bone 20100801 |
| Disposition of bazedoxifene in rats. | Xenobiotica; the fate of foreign compounds in biological systems 20100801 |
| Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. | Current medical research and opinion 20100701 |
| Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. | Climacteric : the journal of the International Menopause Society 20100601 |
| Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. | Climacteric : the journal of the International Menopause Society 20100401 |
| An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. | Molecular endocrinology (Baltimore, Md.) 20100401 |
| Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. | Current opinion in investigational drugs (London, England : 2000) 20100401 |
| Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. | Glia 20100101 |
| Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. | The Journal of steroid biochemistry and molecular biology 20100101 |
| Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. | BMC musculoskeletal disorders 20100101 |
| Cross-geographic region differences in quality of life in women with and without vertebral fracture. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091001 |
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. | Journal of women's health (2002) 20091001 |
| Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. | Fertility and sterility 20090901 |
| Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. | Fertility and sterility 20090901 |
| Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. | Fertility and sterility 20090901 |
| Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. | Fertility and sterility 20090901 |
| New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab. | Current osteoporosis reports 20090901 |
| Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. | Drugs of today (Barcelona, Spain : 1998) 20090701 |
| Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. | Bone 20090601 |
| Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. | Drug metabolism and disposition: the biological fate of chemicals 20090601 |
| Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. | Expert opinion on pharmacotherapy 20090601 |
| Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. | Endocrinology 20090401 |
| The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. | Menopause (New York, N.Y.) 20090101 |
| Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. | Menopause (New York, N.Y.) 20090101 |
| Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. | Menopause (New York, N.Y.) 20090101 |
| Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators. | Menopause (New York, N.Y.) 20090101 |
| Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. | Climacteric : the journal of the International Menopause Society 20090101 |
| Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20081201 |
| The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. | Endocrinology 20081201 |
| [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy]. | Clinical calcium 20081001 |
| Bazedoxifene: a selective estrogen-receptor modulator. | Women's health (London, England) 20080701 |
| Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. | Molecular and cellular endocrinology 20080611 |
| Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424. | Drugs in R&D 20080101 |
| [Status of novel bone-targeting SERMs in development]. | Nihon rinsho. Japanese journal of clinical medicine 20071128 |
| Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. | Expert opinion on investigational drugs 20071001 |
| Update on bazedoxifene: a novel selective estrogen receptor modulator. | Clinical interventions in aging 20070901 |
| Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. | The Annals of pharmacotherapy 20070501 |
| [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene]. | Clinical calcium 20070101 |
| [Next generation selective estrogen receptor modulators]. | Clinical calcium 20060101 |
| Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. | Endocrinology 20050901 |
| Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. | Obstetrics and gynecology 20050601 |
| Bazedoxifene (Wyeth). | Current opinion in investigational drugs (London, England : 2000) 20041001 |
| Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. | Annals of the New York Academy of Sciences 20011201 |
| Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. | Molecular endocrinology (Baltimore, Md.) |